Sumitovant Biopharma Ltd. 4
4 · Myovant Sciences Ltd. · Filed May 15, 2020
Insider Transaction Report
Form 4
Sumitomo Chemical Co., Ltd.
10% Owner
Transactions
- Purchase
Common Stock
2020-05-13$12.38/sh+41,331$511,641→ 48,418,472 total(indirect: See Footnote) - Purchase
Common Stock
2020-05-14$12.02/sh+50,000$600,760→ 48,468,472 total(indirect: See Footnote)
Footnotes (5)
- [F1]This acquisition of a total of 41,331 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the "10b5-1 Trading Plan").
- [F2]The price reported in column 4 is the average stock price.
- [F3]Sumitovant Biopharma Ltd. ("Sumitovant") directly owns 48,418,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. ("Sumitomo Dainippon"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. ("Sumitomo Chemical"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.
- [F4]This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan.
- [F5]Sumitovant directly owns 48,468,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein.